Navigation Links
Genoptix Reports Strong Financial Results For Third Quarter 2007
Date:12/12/2007

134% Increase In Revenues Year-Over-Year

CARLSBAD, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, today reported revenues of $16.2 million for the third quarter ended September 30, 2007, an increase of 134% over revenues of $6.9 million for the comparable period in 2006. For the nine months ended September 30, 2007, the Company reported revenues of $40.8 million, an increase of 152% over revenues of $16.2 million for the comparable period in 2006.

The Company also reported GAAP net income of $3.6 million, or diluted earnings per share (EPS) of $0.06, for the third quarter ended September 30, 2007, compared to a net loss of $0.8 million, or a net loss of $6.07 per diluted share, for the comparable period in 2006. For the nine months ended September 30, 2007, the Company reported net income of $8.7 million, or EPS of $0.10, compared to a net loss of $3.4 million, or a net loss of $34.50 per diluted share, for the comparable period in 2006.

The Company completed its initial public offering (IPO) on November 2, 2007, following the close of the third quarter of 2007. On a pro forma basis, assuming conversion of all outstanding preferred stock, EPS for the three and nine-months ended September 30, 2007 would have been $0.28 and $0.68, respectively (see "Pro Forma Net Income (Loss) Per Share" table below). Further, assuming the IPO was completed at the beginning of each respective period thereby increasing the weighted average shares by 4.7 million, and assuming an effective tax rate of 40%, EPS for the three and nine months ended September 30, 2007 would have decreased from the above pro forma EPS amounts by $0.15 and $0.37, respectively.

"The value of our differentiated service offerings is evidenced by our significant growth in revenue and earnings per share, both of which have increased substantially from just one year ago," said the Company's President and CEO Tina Nova Bennett, Ph.D. "This is our thirteenth consecutive quarter of growth in case volume and revenues, results that further validate our business model. We are proud of our ability to consistently provide specialized, dedicated support to our physician partners and will continue to deliver our high quality services directly to the hematologists and oncologists at the community level."

Gross profit for the quarter improved to $9.7 million, or 60% of revenues, from $3.1 million, or 45% of revenues, for the third quarter of 2006. Gross profit for the nine months ended September 30, 2007 improved to $24.2 million, or 59% of revenues, from $6.9 million, or 43% of revenues, for the comparable period in 2006.

Operating expenses for the quarter increased $2.1 million to $6.0 million from $3.9 million for the third quarter of 2006. In addition, operating expenses for the nine months ended September 30, 2007 increased to $15.3 million from $10.5 million for the comparable period in 2006.

As of September 30, 2007, the Company's cash and cash equivalents were $10.1 million compared to $3.9 million at December 31, 2006. For the nine months ended September 30, 2007, cash generated from operations was $9.1 million, while purchases of capital equipment for the same period totaled $0.8 million, principal payments on notes payable totaled $1.2 million and costs paid in connection with the Company's IPO totaled $1.1 million. Following completion of its IPO in November 2007, the Company received net proceeds of $72.8 million (after underwriting discounts, commissions and estimated offering costs).

"This was a quarter of solid cash generation and improved cost management as we continued to drive strong demand for our unique service offerings," said Sam Riccitelli, Genoptix EVP and COO. "We continued to achieve better than industry average performance in our Days Sales Outstanding metric, or DSOs, which decreased to 54 days as of September 30, 2007."

Performance Outlook

For the full-year 2007, Genoptix expects results from operations to produce revenues of approximately $59 million and net income of approximately $12 million.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company is projecting annualized revenue growth of approximately 50% for the full-year 2008.

Conference Call Information

A conference call will take place on Wednesday, December 12, 2007, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO Tina Nova Bennett, Ph.D., and other members of senior management. The conference call will be webcast live under the investor relations section of the Genoptix website at http://www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The conference call also may be accessed by dialing 866-770-7120 for domestic callers and 617-213-8065 for international callers. The participant code for the call is 28579553. If you are unable to listen to the live webcast, a replay of the call will be available through Monday, January 14, 2008, on the Genoptix website at http://www.genoptix.com.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the success of the Company's business model, the Company's ability to consistently provide specialized, dedicated and high quality services, the Company's growth prospects, DSOs, and the Company's financial guidance for 2007 and 2008. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks and the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. Certain other risks and uncertainties are detailed in the final prospectus for the Company's initial public offering that was filed with the United States Securities and Exchange Commission on October 30, 2007, and in its quarterly report on Form 10-Q for the quarterly period ended September 30, 2007. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Genoptix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

GENOPTIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value)

September 30, December 31,

2007 2006

(unaudited)

Assets

Current assets:

Cash and cash equivalents $10,141 $3,865

Accounts receivable, net of allowance

for doubtful accounts 7,574 4,766

Prepaid expenses and other current assets 619 270

Total current assets 18,334 8,901

Property and equipment, net 1,670 1,287

Other long-term assets 1,262 14

Total assets $21,266 $10,202

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $4,109 $1,987

Accrued compensation 1,780 1,058

Deferred revenue 7 39

Current portion of long-term debt 1,458 1,524

Total current liabilities 7,354 4,608

Deferred rent, net of current portion 319 267

Long-term debt, net of current portion 409 1,262

Commitments and contingencies

Stockholders' equity:

Convertible preferred stock 52 52

Common stock - -

Additional paid-in capital 59,802 59,362

Accumulated deficit (46,670) (55,349)

Total stockholders' equity 13,184 4,065

Total liabilities and stockholders' equity $21,266 $10,202

GENOPTIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

Three Months Nine Months

Ended Ended

September 30, September 30,

2007 2006 2007 2006

Revenues $16,171 $6,911 $40,770 $16,190

Cost of revenues 6,513 3,768 16,543 9,308

Gross profit 9,658 3,143 24,227 6,882

Operating expenses:

Sales and marketing expenses 3,127 1,624 7,869 4,137

General and administrative expenses 2,732 1,985 6,997 4,968

Research and development expenses 143 271 463 860

Impairment and lease exit costs - - - 542

Total operating expenses 6,002 3,880 15,329 10,507

Income (loss) from operations 3,656 (737) 8,898 (3,625)

Other income (expense):

Interest income 118 55 245 193

Interest expense (72) (96) (231) (288)

Other income (1) 7 41 319

Income (loss) before income taxes 3,701 (771) 8,953 (3,401)

Provision for income taxes (114) - (274) -

Net income (loss) $3,587 $(771) $8,679 $(3,401)

Net income (loss) per share (1):

Basic $0.43 $(6.07) $0.82 $(34.50)

Diluted $0.06 $(6.07) $0.10 $(34.50)

Shares used to compute net income

(loss) per share (1):

Basic 239 127 191 99

Diluted 1,674 127 1,635 99

Pro forma net income (loss) per

share (2):

Basic $0.32 $(0.07) $0.77 $(0.31)

Diluted $0.28 $(0.07) $0.68 $(0.31)

Shares used to compute pro forma net

income (loss) per share (2):

Basic 11,271 11,159 11,223 11,131

Diluted 12,772 11,159 12,728 11,131

(1) For purposes of calculating net income per share for the three and

nine months ended September 30, 2007, we first allocated $3,485 of our

net income and $8,522 of our net income, respectively, to preferred

stockholders pursuant to the rights of these preferred stockholders,

resulting in $102 and $157, respectively, of net income allocable to

common stockholders for such periods.

(2) The pro forma net income (loss) per share information assumes the

conversion of all outstanding shares of preferred stock upon the

completion of the IPO as if such conversion had occurred as of the

beginning of each period presented.

GENOPTIX, INC.

PRO FORMA NET INCOME (LOSS) PER SHARE (1)

(in thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Numerator:

Net income (loss) $3,587 $(771) $8,679 $(3,401)

Denominator:

Weighted average shares of common

stock outstanding 318 181 249 160

Weighted avg unvested shares of

common stock subject to repurchase (79) (54) (58) (61)

Adjustments to reflect the weighted

average effect of the assumed

conversion of convertible preferred

stock from the date of issuance 11,032 11,032 11,032 11,032

Pro forma weighted average shares of

common stock outstanding - basic 11,271 11,159 11,223 11,131

Pro forma common equivalent shares

from common and preferred stock

warrants 66 - 61 -

Pro forma common equivalent shares

from options to purchase common

stock and unvested shares of common

stock subject to repurchase 1,435 - 1,444 -

Pro forma weighted average shares of

common stock outstanding - diluted 12,772 11,159 12,728 11,131

Pro forma net income (loss) per share:

Basic $0.32 $(0.07) $0.77 $(0.31)

Diluted $0.28 $(0.07) $0.68 $(0.31)

(1) Pro forma net income (loss) per share and pro forma weighted average

shares of common stock outstanding, basic and diluted, assume the

conversion of all outstanding shares of preferred stock upon the

completion of the IPO as if such conversion had occurred as of the

beginning of each period presented.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc released online ... analyzes nearly 750 unique supply chain notifications and alerts generated by its ... chain risk management practitioners subscribe to the EventWatch service to receive early warnings ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... products to aid in the rapid development and ongoing quality control of molecular ... Virus outbreak is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ...
(Date:2/3/2016)... ... 03, 2016 , ... Big games come and go, but only one will ... country. CereScan, a nationally recognized brain diagnostics and technology company, will join NFL alumni ... vs. NFL Stars Flag Football Game on February 6, 2016. , The event, ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):